Harnessing the Power of the Immune System for Cancer Research
Syngeneic Mouse Models
Advancing Immuno-Oncology Research
Syngeneic Mouse Models offer a powerful and clinically relevant platform for cancer immunotherapy research, enabling researchers to study tumor-immune system interactions in a fully functional immune environment. Unlike traditional xenograft models, these models use murine tumor cell lines in immunocompetent hosts, making them ideal for evaluating immune checkpoint inhibitors, CAR-T therapies, monoclonal antibodies, and combination treatments.
With a diverse tumor model library covering solid tumors and hematologic malignancies, Medicilon’s syngeneic models provide realistic tumor-immune interactions, customizable immune profiling, and scalable studies to support disease-relevant, mechanistic, and translational oncology research.
Checkpoint Inhibitor Testing
Assess response to PD-1/PD-L1, CTLA-4, and other immune-modulating therapies.
Immune Cell Infiltration Studies
Analyze T-cell, macrophage, and dendritic cell activity to understand tumor-immune interactions.
Combination Therapy Development
Optimize strategies by integrating chemotherapy, radiation, and immunotherapies for enhanced treatment efficacy.
Next-Generation CAR-T & Monoclonal Antibody Research
Explore novel immunotherapies to unlock personalized cancer treatment breakthroughs.
Syngeneic Mouse Models
Medicilon offer a portfolio of syngeneic tumor models, allowing researchers to conduct highly specific, immune-relevant studies across multiple cancer types.
Our Available Syngeneic Mouse:
Cancer Type
Available Cell Lines
- Brain Cancer
G261
- Breast cancer
4T1, EMT6, JC, E0771
- Colon Cancer
CT26.WT, MC-38, Colon26
- Leukemia
C1498, L1210, WEHI-3
- Liver Cancer
H22, Hepa 1-6
- Lung cancer
LLC1, KLN205
- Lymphoma
A20, EL4, L5178-R, E.G7-OVA
- Mastocytoma
HT1080-luc
- Melanoma
B16-F10, Clone-M3, B16-F0
- Myeloma
J558
- Pancreas cancer
Panc 02
- Penal Cancer
RENCA
- Urinary Blader Cancer
- Sarcoma
WEHI-164, S180
Let’s Drive Immuno-Oncology Innovation Together
At Medicilon, we don’t just offer models – we provide end-to-end support for your oncology research. Our team of highly experienced scientists and cutting-edge facilities ensure:
- Fast, high-quality study execution to keep your research moving forward.
- Data-driven insights for more informed decision-making.
- Customized research solutions tailored to your specific drug development needs.
How Orthotopic Models Power Cancer Research
Key Models highlights
- Testing Drug Efficacy in a Natural Tumor Environment: Get accurate data on tumor growth inhibition, drug penetration, and therapeutic impact.
- Metastasis Research: Study how cancer spreads, test anti-metastatic therapies, and track tumor dissemination in real-time.
- Combination Therapy Development: Evaluate the effectiveness of multi-drug regimens and optimize treatment strategies.
- Immune System & Tumor Microenvironment Studies: Explore how tumors interact with immune cells, aiding in the development of immunotherapies.
Tumor
Neurological disease
Digestive system disease
Metabolic disease
Cardiovascular diseases
Inflammatory & immune disease
Other disease models
Let’s Drive Immuno-Oncology Innovation - Together
At Medicilon, we don’t just offer models – we provide end-to-end support for your oncology research. Our team of highly experienced scientists and cutting-edge facilities ensure:
- Fast, high-quality study execution to keep your research moving forward.
- Data-driven insights for more informed decision-making.
- Customized research solutions tailored to your specific drug development needs.
Tumor Models
Non-tumor Models
cancer therapy INNOVATION
Integration Across Oncology Models
Medicilon provides a full suite of preclinical models, ensuring a smooth transition between different research phase.
Tumor models:
Medicilon provides a comprehensive range of oncology models, including:
- CDX Models – Rapid, cost-effective screening for early-phase drug development.
- PDX Models – Clinically relevant, patient-matched models for personalized therapy research.
- Orthotopic Models – Study tumor progression in its native environment for improved therapeutic evaluation.
- Humanized Mouse Models – Bridge the gap between preclinical and clinical immunotherapy studies.
By leveraging syngeneic models alongside other in vivo platforms, researchers can refine drug candidate selection, reduce clinical trial failure rates, and accelerate the path to breakthrough therapies.
